本帖最后由 老马 于 2013-3-13 13:43 编辑 3 T+ H S5 H [' Y9 {* I, A; }
5 w3 l. p6 ^- B& Q, I d- i9 W, S
健择（吉西他滨）+顺铂+阿瓦斯汀
, W% E7 E( [( ~7 Q' A. ? Gemzar +Cisplatin + Avastin
# l8 ^. g3 f# F! p" Ohttp://annonc.oxfordjournals.org/content/21/9/1804.full s& V1 V. |2 b) X
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
! T# M: i8 l; j. Z( s, N+ pPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. * V5 V! G6 {& K1 U& m
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
( \0 n7 B' Z0 S9 L$ s! o
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 1141)
* @* P8 M! W, ~# M% z华为网盘附件：& W5 B$ m$ r% y/ t
【华为网盘】ava.JPG) `+ K- V& O# d4 d' M: e
|
11011102001537 )
显身卡
